Compare RLMD & BHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | BHK |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.9M | 668.8M |
| IPO Year | 2012 | N/A |
| Metric | RLMD | BHK |
|---|---|---|
| Price | $5.93 | $8.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $12.40 | N/A |
| AVG Volume (30 Days) | ★ 925.0K | 348.9K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.34% |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.74 |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.52 | $8.69 |
| 52 Week High | $8.00 | $10.12 |
| Indicator | RLMD | BHK |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 41.18 |
| Support Level | $5.68 | N/A |
| Resistance Level | $7.46 | $9.07 |
| Average True Range (ATR) | 0.41 | 0.08 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 5.11 | 51.32 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its managed assets in bonds that are investment-grade quality at the time of investment. The trust, under a normal market scenario, will invest in a range of bonds, including corporate bonds, U.S. government and agency securities, and mortgage-related securities.